CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

insulin glargine

Last Updated: January 6, 2020
Result type: Reports
Project Number: SE0589-000
Product Line: Reimbursement Review

Generic Name: insulin glargine

Brand Name: Semglee

Manufacturer: BGP PHARMA ULC

Therapeutic Area: Diabetes mellitus, Type 1 & 2

Indications: Diabetes mellitus, Type 1 & 2

Manufacturer Requested Reimbursement Criteria1: To be listed as the preferred insulin glargine treatment for patients who have been diagnosed with type 1 or type 2 diabetes requiring long-acting insulin.

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: Yes

Companion Diagnostics: No

Fee Schedule: Schedule D

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedOctober 16, 2018
Patient group input closedDecember 04, 2018

- Patient input submission received from Diabetes Canada

Patient input summary sent for review to patient input groupsDecember 12, 2018
Patient group comments on input summary closedDecember 19, 2018

- Patient input summary feedback received

Submission receivedNovember 14, 2018
Submission accepted for reviewNovember 29, 2018

- Submission was not accepted for review on 21 Nov 2018

Review initiatedNovember 30, 2018

- Voluntarily withdrawn by the manufacturer on 2019-Mar-05